On October 13, 2022, Department of Health and Human Services (HHS) Secretary Alex Azar extended the COVID-19 Public Health Emergency (PHE) declaration, on the day it was set to expire, for an additional 90 days. The PHE is now set to expire January 13, 2023.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) today released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The statement was published in the AACR’s journal Clinical Cancer Research and ASCO’s Journal of Clinical Oncology.
On August 4, 2022, the Department of Health and Human Services (HHS) issued a proposed rule on Section 1557 (first finalized in May 2016) of the Affordable Care Act (ACA), which prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in certain health programs and activities.
As expected in the lead-up to midterm elections, Congress today (September 30) passed a continuing resolution (CR) that funds the government through December 16, 2022, avoiding a government shutdown and giving Congress more time to negotiate critical funding decisions for Fiscal Year 2023.
In response to the recent Supreme Court decision, ASCO has developed and compiled resources related to reproductive health in patients with cancer to help members navigate changes and ensure patient access to high-quality cancer care.
The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support for cancer research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) are vital in our nation’s efforts to combat and ultimately cure diseases like cancer.
During the 2022 state legislative session, the Association for Clinical Oncology (ASCO) and state societies teamed up to advocate for policies aimed at improving access to equitable, high-quality cancer care. ASCO has tracked more than 500 state bills and has submitted 46 letters and counting to state legislators to address various policy developments, from access to care to utilization management.
ASCO is committed to the delivery of medically appropriate, equitable, evidence-based cancer care. For patients of child-bearing age, a cancer diagnosis raises medical considerations around pregnancy and fertility preservation. Every patient should have the ability to pursue, in partnership with their oncologist, all treatment options that offer the best chance of a successful outcome for their cancer.
From June 10-15, delegates from the Association for Clinical Oncology (ASCO) participated in the 2022 Annual Meeting of the American Medical Association’s (AMA) House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and establish association policies. This year, the meeting returned to an in-person format in Chicago.
The AMA HOD voted to approve two ASCO-backed resolutions during the meeting:
Last week, American Society of Clinical Oncology (ASCO) CEO Clifford A. Hudis, MD, FACP, FASCO, participated in Health Equity: Advocacy and Access, an online panel hosted by The Cancer Letter which focused on role of policy in ensuring equitable access to care.
Today, JCO Oncology Practice, a journal of the American Society of Clinical Oncology (ASCO), published a special series that examines the causes of disparities in cancer care and outcomes in the U.S. Hispanic/Latinx population and offers potential solutions to increase equity among this group. "Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States” features 18 articles and editorials that present new data and opportunities on a wide variety of topics, including prevention and screening, genetic testing, clinical trial enrollment and participation, access to affordable health care, and workforce representation, among others.
The Food and Drug Administration (FDA) recently announced two proposed rules. One proposal would ban menthol as a characterizing flavor in cigarettes, and the other would ban all characterizing flavors (other than tobacco) in cigars.
The American Society of Clinical Oncology (ASCO) today announced the establishment of the ASCO Center for Equity, Diversity, and Inclusion, which will advance the Society’s equity, diversity, and inclusion (EDI) goals across the organization and throughout the wider oncology community.
ASCO stands with our Ukrainian members, the worldwide oncology community, and healthcare providers around the globe in condemning Russia’s unprovoked war on Ukraine. We call for an immediate cessation of these hostilities and demand full protection and safety for all Ukrainian patients, healthcare workers, and medical facilities.
In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer